Ritu Salani MD MBA
Gynecologic Oncology
Professor, Obstetrics and Gynecology, University of California, Los Angeles
Join to View Full Profile
100 Medical Plaza, Suite 383Los Angeles, CA 90095
Phone+1 310-794-7274
Fax+1 310-794-7274
Dr. Salani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ritu Salani is an experienced Obstetrics & Gynecology specialist based in Los Angeles, CA. She has particular expertise in Gynecologic Oncology, gained during her fellowship at Johns Hopkins University, following her residency at Emory University School of Medicine. She currently serves as a professor at the Ronald Reagan UCLA Medical Center. Dr. Salani's clinical practice involves chemotherapy, immunotherapy, and treatments for uterine carcinoma, hereditary breast/ovarian cancer, among others. She has numerous publications in reputed journals and has been involved in several clinical trials focused on treating advanced, persistent, or recurrent cervical cancer. Recognition for her contributions includes the CMS Meaningful Use Stage 1 Certification and being named a Fellow by the American Congress of Obstetricians and Gynecologists.
Education & Training
Johns Hopkins UniversityFellowship, Gynecologic Oncology, 2005 - 2008
Emory University School of MedicineResidency, Obstetrics and Gynecology, 2001 - 2005
Northeast Ohio Medical UniversityClass of 2001
Certifications & Licensure
CA State Medical License 2020 - 2026
OH State Medical License 2008 - 2022
MD State Medical License 2006 - 2009
GA State Medical License 2003 - 2005
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian Start of enrollment: 2010 Sep 01
- Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Publications & Presentations
PubMed
- Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.Alexandra H Smick, Lindsay Brennan, Jordyn Silverstein, Ritu Salani, Gottfried Konecny
International Journal of Gynecological Cancer. 2025-10-01 - Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development.Victoria Cerda, Bobbie J Rimel, Jacob Mercer, Michael A Thompson, Denise Shieh
International Journal of Gynecological Cancer. 2025-09-29 - The relationship between sexual activity during chemotherapy and sexual functioning after treatment among females with breast and gynecologic cancer.Kristen M Carpenter, Katherine Conroy, Lora L Black, Ritu Salani, Maryam Lustberg
Supportive Care in Cancer. 2025-08-28
Journal Articles
- An Ecological Evaluation of the Increasing Incidence of Endometrial Cancer and the Obesity EpidemicStacy A Smrz, Corinne Calo, Ritu Salani, American Journal of Obstetrics and Gynecology
Authored Content
- Disappointing but Important: Cervical Cancer OUTBACK Trial’s Negative ResultsJune 2021
Press Mentions
Presidential Matters: Amanda Nickles Fader, MDFebruary 10th, 2025- SGO Ways to Wellness: An Open Letter to My Former SelfJanuary 6th, 2025
- CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian CancerMarch 26th, 2023
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
